IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by EverSource Wealth Advisors LLC

EverSource Wealth Advisors LLC increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 9.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,482 shares of the medical research company’s stock after purchasing an additional 131 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in IQVIA were worth $291,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. FMR LLC increased its stake in shares of IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after buying an additional 804,963 shares during the period. Cantillon Capital Management LLC increased its position in shares of IQVIA by 12.3% in the 4th quarter. Cantillon Capital Management LLC now owns 2,066,144 shares of the medical research company’s stock valued at $406,018,000 after purchasing an additional 226,017 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares during the last quarter. Nordea Investment Management AB grew its stake in shares of IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in IQVIA by 3.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,246,890 shares of the medical research company’s stock valued at $245,026,000 after buying an additional 44,991 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 2.2 %

Shares of IQVIA stock opened at $185.40 on Friday. The company has a market cap of $32.69 billion, a P/E ratio of 24.72, a PEG ratio of 1.99 and a beta of 1.50. The firm has a fifty day moving average of $196.63 and a two-hundred day moving average of $210.69. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a one year low of $179.28 and a one year high of $256.34.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of recent analyst reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a report on Monday, February 10th. William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Robert W. Baird reduced their price objective on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, January 21st. Stifel Nicolaus dropped their target price on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Finally, Citigroup reduced their price target on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Five equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.